187 related articles for article (PubMed ID: 36439885)
1. Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8
Chang M; He Y; Liu C; Lin R; Huang X; Liang D; Zhang J; Lu Y
Int J Biol Sci; 2022; 18(16):6035-6051. PubMed ID: 36439885
[No Abstract] [Full Text] [Related]
2. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
3. WHSC1/NSD2 regulates immune infiltration in prostate cancer.
Want MY; Tsuji T; Singh PK; Thorne JL; Matsuzaki J; Karasik E; Gillard B; Cortes Gomez E; Koya RC; Lugade A; Odunsi K; Battaglia S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589522
[TBL] [Abstract][Full Text] [Related]
4. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
5.
Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract][Full Text] [Related]
7. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
8. GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer.
Peng Q; Xie T; Wang Y; Ho VW; Teoh JY; Chiu PK; Ng CF
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203661
[TBL] [Abstract][Full Text] [Related]
9. LINC00152 mediates CD8
Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J
J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190
[TBL] [Abstract][Full Text] [Related]
10. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
[TBL] [Abstract][Full Text] [Related]
11. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
12. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
16. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance.
Zhou Q; Yang C; Mou Z; Wu S; Dai X; Chen X; Ou Y; Zhang L; Sha J; Jiang H
Cancer Sci; 2022 Nov; 113(11):3698-3709. PubMed ID: 36018546
[TBL] [Abstract][Full Text] [Related]
18. SNAP25 is a potential prognostic biomarker for prostate cancer.
Di L; Gu M; Wu Y; Liu G; Zhang L; Li Y; Zhang W
Cancer Cell Int; 2022 Apr; 22(1):144. PubMed ID: 35392903
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis the diagnosis, malignant progression and immune infiltrate of ANXA6 in prostate cancer.
Huang B; Yang K
Genes Genomics; 2023 Sep; 45(9):1197-1209. PubMed ID: 37311953
[TBL] [Abstract][Full Text] [Related]
20. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
